Absence of Opioid Withdrawal Symptoms in Patients Receiving Methadone and the Protease Inhibitor Lopinavir‐Ritonavir
Open Access
- 15 April 2002
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 34 (8), 1143-1145
- https://doi.org/10.1086/339541
Abstract
A study was designed to determine the interactions, both clinical and pharmacokinetic, between methadone and lopinavir-ritonavir. Results demonstrated a 36% reduction in the methadone area under the plasma concentration—time curve after the introduction of lopinavir-ritonavir, with no coincident symptoms of opioid withdrawal and no requirement for methadone dose adjustment.Keywords
This publication has 5 references indexed in Scilit:
- Pharmacokinetic Interactions of Nevirapine and Methadone and Guidelines for Use of Nevirapine to Treat Injection Drug UsersClinical Infectious Diseases, 2001
- Effect of Ritonavir/Saquinavir on Stereoselective Pharmacokinetics of Methadone: Results of AIDS Clinical Trials Group (ACTG) 401JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- The pharmacokinetics of methadone in HIV‐positive patients receiving the non‐nucleoside reverse transcriptase inhibitor efavirenzBritish Journal of Clinical Pharmacology, 2001
- Antiretroviral Therapy in AdultsJAMA, 2000
- Enzyme induction and inhibitionPharmacology & Therapeutics, 1990